Hospital de Pediatría “Prof. Dr. Juan P. Garrahan”.

Slides:



Advertisements
Similar presentations
Objective of the DAP A) Specify an analysis plan that can be applied to a wide variety of clinical HIV resistance studies. B) Include both Intervention.
Advertisements

Virologic and immunologic response following antiretroviral therapy initiation among pregnant and postpartum women with acute HIV-1 infection: MOPDB0101.
Protective HLA Class I alleles are associated with reduced immune activation in Primary HIV infection Elizabeth Hamlyn 1, Stephen Hickling 2, Abdel Babiker.
Trends in HIV prevalence and HIV incidence in South Africa Thomas M. Rehle, MD, PhD Human Sciences Research Council (HSRC) Cape Town, South Africa AIDS.
ACTG 333 The Antiviral Effect of Switching from Saquinavir to the New Formulation of Saquinavir vs. Switching to Indinavir After >1 year of Saquinavir.
A Collaborative Analysis of Data from Cohorts in Thailand, South Africa, Botswana, and the United Kingdom International Collaborative Study of Pediatric.
Introduction DCDOH supports HIV test and treat activities - increased number of HIV tests performed, emphasis on earlier linkage to care. Limited data.
Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy S. Fourati 1, R. Calin 2, G. Carcelain 3, P.
Long-term ART initiated during primary HIV-1 infection limits the HIV-1 reservoir size but not to levels found in LTNPs Eva Malatinkova, Ward De Spiegelaere,
Future ART options for HIV-infected children exposed to maternal HAART Lee Kleynhans Experts Roundtable June 2008.
Modified Directly Observed Therapy for First Virologic Failure: ACTG A5234 PI Dr A Chisada Presenter: Dr W Samaneka MBChB, MSc UZ-UCSF ARD 17 April 2015.
Older and wiser: continued improvements in clinical outcome and highly active antiretroviral therapy (HAART) response in HIV-infected children in the UK.
Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to March 2009* * Numbers are based on reports received rather than children seen to.
The Immunologic Efficacy of Antiretroviral Therapy among HIV-infected Patients in North America and Africa Elvin Geng* 1, Eric Vittinghoff 1, Jean Nachega.
Transition Program of HIV-infected adolescents to Adult HIV care in Buenos Aires, Argentina S. Arazi Caillaud 1, D. Mecikovsky 1, A.Bordato.
Determinants of long term adherence to antiretroviral drugs among adults followed over 54 months in Dakar (Senegal) M. Ciss 1, A. Desclaux 2, K. Diop 3,
Impact of Highly Active Antiretroviral Therapy on the Incidence of HIV- encephalopathy among perinatally- infected children and adolescents. Kunjal Patel,
Life expectancy of patients treated with ART in the UK: UK CHIC Study Margaret May University of Bristol, Department of Social Medicine, Bristol.
EARLY CHILDHOOD OUTCOMES AT THE BOTSWANA- BAYLOR CHILDREN’S CLINICAL CENTRE OF EXCELLENCE: A REPORT TO THE WHO TECHNICAL REFERENCE GROUP ON PEDIATRIC CARE.
Poster # 388 CROI Feb Montreal, Canada Association of HIV-1 Co-receptor Tropism with Immunologic and Virologic Parameters in HIV-1 infected,
Neurocognitive Impairment in HIV-Infected Subjects on HAART: Prevalence and Associations Kevin Robertson *1, Kunling Wu 2, Thomas Parsons 1, Ron Ellis.
Engagement in the HIV care cascade among transgender women enrolled in a public HIV clinic in Buenos Aires, Argentina, M.E. Socías 1,2, O. Sued.
Immune Discordance on Highly Active Antiretroviral Therapy Can Still be Regarded as a Therapeutic Success Nur F. Önen MD, MRCP 1, Rachel Presti MD PhD.
The effect of tuberculosis treatment on virologic and immunologic response to combination antiretroviral therapy among South African children Heidi M.
1 The impact of ongoing illicit drug use on virologic suppression in HIV-infected injection drug users receiving HAART Authors: Harout Tossonian, Jesse.
Comparison of NNRTI vs PI/r  EFV vs LPV/r vs EFV + LPV/r –A5142 –Mexican Study  NVP vs ATV/r –ARTEN  EFV vs ATV/r –A5202.
Supported by: NIAID/NHLBI R24 AI067039, NIAID R21 AI Viremia copy-years: A measure of cumulative HIV burden among patients initiating antiretroviral.
Progressive histological liver improvement after sustained virological response to therapy in HCV / HIV coinfected patients. Jose L. Casado,
Persistent immune activation despite suppressive HAART is associated with higher risk for viral blips in HIV-1 infected individuals Alexander Zoufaly 1.
INTRODUCTION A previous cohort study from our unit suggested a benefit for the use of efavirenz compared to nevirapine in a group of patients initiating.
T-cell activation positively correlates with cell-associated HIV-DNA level in PBMCs in viremic patients with acute or chronic HIV-1 infection Laurence.
OUTCOME OF STAVUDINE INDUCED PERIPHERAL NEUROPATHY IN HIV-1 POSITIVE PATIENTS SWITCHED OR SUBSTITUTED TO A NON-STAVUDINE- BASED REGIMEN Dr P Gorejena-Chidawanyika.
HIV co-receptor tropism in treatment-naïve patients: impact on CD4 decline and subsequent response to HAART Laura Waters, Sundhiya Mandalia, Adrian Wildfire,
First-Line Treatment of HIV Infection With Either NNRTI- or PI-Based Regimens Effective for Long-term Disease Control Slideset on: MacArthur RD, Novak.
1 Predictors of virological failure in a Cambodian setting Sokkab An, M.D Sihanouk Hospital Center of HOPE (SHCH), Phnom Penh, Cambodia.
HIV Drug Resistance Surveillance Satellite Session: HIV Drug Resistance Surveillance and Control: a Global Concern Silvia Bertagnolio, MD WHO,
Group Work Recommendations- what to start Group WHAT 1.
#AIDS2016 Dolutegravir (DTG) plus Rilpivirine (RPV) in Suppressed Heavily Pretreated HIV-Infected Patients A. Díaz, J.L. Casado, F.
Genotype-directed dosing for Efavirenz
Switch to PI/r monotherapy
Viral and Host characteristics of a child with perinatal HIV-1 after prolonged period of ART cessation in the CHER trial Avy Violari, Mark Cotton, Louise.
Emory University School of Medicine Department of Medicine
Higher HDL, better brain
Earlier treatment and lower mortality in infants Initiating ART at
Abstract THDB1016 Treatment cascade of HIV-infected infants in the Thailand National Program: How close are we to the target?   1 Thanyawee.
Title Factors associated with viral suppression among adolescents living with HIV in Cambodia “No conflicts of interest to declare”
undetectable (undetectable-6.25)
Factors affecting virological failure in patients receiving antiretroviral therapy: a prospective HIV Clinical cohort in rural Uganda. Patrick Kazooba1,
No Conflicts of Interest to declare.
Tolerability of Isoniazid Preventive Therapy (IPT) in an HIV infected cohort
Berket Yemane, Melaku Umeta, Fikre Enquselassie, Wondwossen Amogne
The Effect of Family Social Intervention on Treatment Response in Children with HIV Infection Francine Cheng DO, Janak Patel MD, Debbie Konopik SWA, and.
Better Retention Rates Observed in Patients on Lopinavir than Atazanavir in Uganda
Intensification with INSTI
San Francisco Department of Public Health
Immunologic and virological response to ART among HIV infected individuals at a tertiary hospital in Ghana ¹Obiri-Yeboah Dorcas, School of Medical Sciences,
Cepheid Symposium, IAS 23rd July 2018
24 July 2018 Treatment outcomes with bedaquiline use when substituted for second-line injectables in multidrug resistant tuberculosis: a retrospective.
Towards the last 90% of the 90:90:90 strategy: A review of viral suppression rates in a HIV program in Central and Eastern Kenya Dr Moses Kitheka,
Long-Term Clinical and Immunologic Outcomes Are Similar in HIV-Infected Persons Randomized to NNRTI versus PI versus NNRTI+PI-based Antiretroviral Regimens.
Comparison of NNRTI vs PI/r
Switch to LPV/r monotherapy
Switch to RAL-containing regimen
Intensification with INSTI
Comparison of PI vs PI ATV vs ATV/r BMS 089
Switch to ATV/r monotherapy
Switch to LPV/r monotherapy
Switch to LPV/r monotherapy
Treatment Outcome among patients on ART in Southern Tanzania: Does Time of ART initiation Matter?
Public Health Implications
Presentation transcript:

Hospital de Pediatría “Prof. Dr. Juan P. Garrahan”. Dynamics of HIV-1 DNA in Children Over Long-term Sustained Viral Suppression: Impact of the Time of Infection at Viral Control on Reservoir Size M. Moragas, M. Distefano, D. Mecikovsky, S. Arazi Caillaud, R. Bologna, P. Aulicino, A. Mangano. Hospital de Pediatría “Prof. Dr. Juan P. Garrahan”.

Conflict of Interest No conflicts of interest to declare.

Aims To determine the decay of viral reservoirs throughout sustained virological suppression in perinatally infected children. How the time to achieve effective ART response affects the persistence of HIV-1.

Design and Methodology A retrospective study including 37 HIV-1 perinatally infected children born between 1990-2008. At least sustained viral suppression during 4 years. Total HIV-DNA was quantified by semi-nested real time PCR, and analyzed longitudinally by linear mixed-effect model. 2-LTR circles were detected by hemi-nested real time PCR and followed over VS by logistic regression.

Infant Characteristics Value Subjects, No. 37 Sex, No. (%), Female 19 (51.4) ACTG 076 prophylaxis regimen, No. (%)   None 24 (64.9) Partial 5 (13.5) Complete Unknown 3 (8.1) Age at ART initiation, median (IQR), yrs 2.4 (0.8-5.1) First ART regimen, No. (%) 2 NRTIs + NNRTI 16 (43.2) 2 NRTs + PI 21 (56.8) Age at VS, median (IQR), yrs 5.3 (3.8-10.8) ART regimen at VS, No. (%) 23 (62.2) 14 (37.8) pVL at pre-VS, median (IQR), log10 copies/mL 5.89 (5.03-6.25)

Total HIV-DNA and 2-LTRs have a strong decay during the first two years of VS  Variable Values in PBMCs No. of children 37 Intercept Estimated (95% CI) 2.44 (2.17 to 2.70) First slope (0-2 yrs) Estimated ( 95% CI) -0.26 (-0.43 to -0.09) P-value .0028 Second slope (2-4 yrs) -0.06 (-0.15 to 0.55) .2578 Level of CA-HIV-DNA (log10 cpm) At 0 yrs of VS, mean (95% PI) 2.55 (2.18 to 2.93) At 2 yrs of VS, mean (95% PI) 2.03 (1.79 to 2.27) At 4 yrs of VS, mean (95% PI) 1.98 (1.66 to 2.30) Piecewise linear mixed-effect model. 2-LTRs circles - At VS: 82.9% (29/35) - At 2 yrs. of VS: 37.5% (9/24) At 4 yrs. of VS: 28.1% (9/32) Significant decay (P=.0009) 2-LTRs = CA-HIV-DNA 2.48 (IQR: 1.68 to 3.01) vs. 1.89 (IQR: 0.78 to 2.39) log10 cpm (P<.005).

Decay of total HIV-DNA according to the age at VS  Variable Time of Infection at VS ≤1.5 yrs >1.5-4 yrs >4 yrs P-value No. of children 4 6 27 NA Intercept Estimated (95% CI) 2.44 (2.18 to 2.70) 2.44 (2.18 to2.70) First slope (0-2 yrs) Estimated ( 95% CI) -0.51 (-0.94 to -0.07) -0.35 (-0.83 to 0.14) -0.21 (-0.39 to -0.02) .1645 .0235 .1583 .0287 Second slope (2-4 yrs) -0.001 (-1.50 to 1.50) -0.11 (-1.64 to 1.44) -0.07 (-0.63 to 0.49) .7346 .3477 .6495 .4798 Level of CA-HIV-DNA (log10 cpm) At 0 yrs of VS, mean (95% PI) 2.73 (2.01 to 3.45) 2.58 (1.86 to 3.30) 2.52 (2.13 to 2.90) .5941 At 2 yrs of VS, mean (95% PI) 1.72 (1.24 to 2.20) 1.89 (1.40 to 2.37) 2.11 (1.85 to 2.37) .1614 At 4 yrs of VS, mean (95% PI) 1.56 (0.75 to 2.37) 1.83 (0.94 to 2.73) 2.08(1.73 to 2.43) .1942

Discussion These data highlight the difficulty to eliminate the circulating reservoirs from peripheral blood, reinforcing the clinical benefit of very early effective therapy in perinatally infected children. Peripheral blood HIV-1 reservoir size decayed markedly during the first two years of VS. Children with VS before 18 months tended to have a higher decay rate. After two years of VS peripheral blood HIV-1 reservoirs decay very slowly and independently of the time to achieve VS.

Acknowledgement